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ABSTRACT 
Nanoparticles for Biomedical Applications: Photothermal Therapy and 
Nuclear Delivery 
by 
Taeyjuana Y. Curry 
 
Chair: Raoul Kopelman 
Cancer is still a grand challenge faced by society today. Nanomedicine 
addresses many of the serious issues associated with conventional treatments. 
Nanoparticles (NPs) are advantageous for therapy because they are minimally 
invasive, have tunable characteristics and can be used as targeted and 
multifunctional treatment platforms.  
This thesis focuses on the use of both polymeric and gold NPs for 
photothermal therapy (PTT) of cancer cells, and describes the surface 
engineering of gold NPs for optimized, cell specific nuclear delivery.  The first 
ever use of the FDA approved Coomassie Brilliant blue (CB) dye as a 
photosensitizer for PTT of cancer is detailed.  The CB dye is covalently linked 
into the matrix of biologically compatible, hydrogel NPs. Also, a portable, 
inexpensive, low intensity LED is used as the light source. Incubation with 
moderate NP concentrations, combined with relatively low light levels, yielded 
nearly complete cell death within 3 hours of treatment.   
xviii 
 
Another part of this dissertation research describes the stepwise surface 
engineering of specialty gold NPs for optimized delivery to cancer cell nuclei.  
These femtosecond laser ablation generated gold NPs have virgin surfaces to 
which cell-specific and nucleus-specific targeting peptides are directly attached.  
Efficient nuclear delivery was achieved using as little as 100pM of NPs solution, 
a concentration that is at least an order of magnitude lower than what has been 
previously reported in nuclear delivery studies involving gold NPs.  
The aforementioned nuclear-targeted gold NPs were also successfully 
utilized for PTT of cancer cells in vitro. A drastic difference in treatment efficacy 
was observed when the therapy was mediated by gold NPs delivered into the 
nucleus compared to when the NPs remained outside the nucleus.  In the former 
case, the cell viability drops dramatically at early times and complete cell death is 
observed at six hours post-treatment. In the latter case, the viability decreases 
slowly over time and a maximum change of approximately 50% is observed 12 
hours post-treatment.  
Overall this thesis provides several contributions to the field of 
Nanobiotechnology, through the presentation of highly effective, nanoparticle-
mediated PTT. The latter can be easily incorporated into a multimodal approach 
for the treatment of cancer. 
 
 1 
Chapter 1 Introduction 
 
 
1.1 Motivation & Background 
In the last decade, nanoparticles have emerged as effective platforms for 
diagnostics, imaging, sensing, and therapeutic studies in numerous fields of 
research.  This emergence has facilitated major research breakthroughs 
including cancer diagnosis and treatment1,2, early detection of chronic and 
debilitating diseases3,4, rapid detection of bacteria growth for evaluation of 
antibiotic effectiveness5,6, imaging enhancement, and intracellular sensing 7,8.  
The increase and sustained growth in nanoparticle research primarily 
resides in its many advantages over more conventional techniques, which 
include the ability for non-invasive, quantitative and qualitative measurements of 
many physical and chemical intracellular processes. These measurements are 
usually achieved through facile incorporation of various molecular sensing agents 
into the nanoparticle platform, as well as surface modifications. Furthermore, 
nanoparticles provide an avenue through which a concentrated amount of 
sensing, diagnostic, or therapeutic agent, or a combination of two or more of 
these, can be delivered to target cells. This is more advantageous than other 
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methods of intravenous administration of dyes and drugs in which only low local 
concentrations are usually achieved due to the global spreading of the dose.   
Another advantage associated with nanoparticles is the tunability of their 
size, shape, absorption, and surface characteristics.  Nanoparticles sizes range 
from a few nanometers to hundreds of nanometers, and the currently employed 
shapes are variable and usually dictated by the nature of their purpose.  Usually, 
the size and shape of the nanoparticles are easily adjusted during fabrication, 
using wet lab techniques.  Nanoparticles can be shaped like spheres, stars, rods, 
pyramids, barbells, cylinders, etc., and can also be solid or hollow 
(“nanobottles”).  Additionally, nanoparticle matrices greatly vary, depending on 
the intended purpose and the nature of the study; their structure can range from 
being metallic, polymeric, ceramic, carbon, or a hybrid thereof.   Nanoparticle-
mediated sensing, imaging, and therapy are three of the primary ways in which 
nanoparticles are currently being successfully used in academic research, and 
for clinical and industrial applications; however, this introductory chapter will 
focus on academic studies. 
 
1.1.1   Nanoparticle-mediated Sensing 
The ability to measure chemical and physical processes within a live cell 
in real time enables early detection of diseased cells, evaluation of a previously 
applied treatment, and the ability to monitor internal responses to changes in the 
cell environment, among other things.  In particular, intracellular ion sensing is of 
substantial interest because of the important role ions play in maintaining healthy 
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physiological conditions within the cell.  To this end, various molecular probes 
have been identified or fabricated for intracellular ion sensing; however, initial 
research studies involving these probes were plagued by many drawbacks, 
including nonspecific binding within the cells which led to reduced sensing 
capabilities, sequestration in cell compartments devoid of the ion of interest, 
interaction with other cell processes, and measureable toxicity.   Nanoparticle-
mediated intracellular sensing offers many advantages over other conventional 
forms of intracellular sensing, such as patch clamps and micro-optodes and 
electrodes. These advantages include being noninvasive, providing a biologically 
inert barrier between the sample and the sensor, enabling real time 
measurements, and facilitating sensing capabilities of multiple analytes in 
parallel.  
The Kopelman group has a long-standing history sensing research, 
involving ions, molecules and radicals, by the use of so-called “PEBBLEs,” an 
acronym for Photonic Explorers for Bioanalysis in Biologically Localized 
Embedding; a schematic of some of the most commonly utilized PEBBLE 
schemes is shown in Figure 1.1A-1.1C.   The PEBBLEs were fabricated using 
various nanoparticle matrices, including cross-linked polyacrylaminde, organically 
modified silane, cross-linked poly(decylmethacrylate), ormosil and sol-gel silica, 
and have been utilized for intracellular sensing of  many ions, molecules and 
radicals,  including H+, Ca2+, K+, O2,  Zn2+ , Cl-,  Na+, Mg 2+, Cu2+, as well as O2, 
H2O2,  glucose and NO, OH, etc. 8-16.  The general premise guiding these studies 
involves the incorporation and/or encapsulation of, among others, ion sensitive 
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dyes within the nanoparticle matrix, thereby addressing many of the above 
mentioned drawbacks associated with simply staining the cells with “naked” 
molecular probes.   For example, in a recent study conducted by Di Si, et al. 8, a 
rhodamine-based Ca2+  dye was loaded into the interior of nanoPEBBLEs, with a 
reference dye, Hilyte Fluor 647, conjugated to the nanoparticle matrix, shown in 
Figure 1.1D.  The study demonstrated that this type of nanoparticle construction 
avoids many of the issues commonly associated with intracellular Ca2+ sensing. 
The study also illustrated reliable, ratiometric intracellular measurements, a lack 
of nonspecific binding of the sensing dye to intracellular proteins, or dye leaching, 
and avoiding subsequent sequestration into organelles.  Furthermore, the 
incorporation of the sensing dye into the nanoparticle matrix enabled a high 
certainty that the calibration completed in solution in vitro, prior to treating the 
cells, remained accurate once the nanoPEBBLEs were inside of the cells.8   
Another notable study conducted within the Kopelman group involved the 
successful fabrication of 30nm targeted oxygen sensors for intracellular use 17, 
shown in Figure 1E.  As in the previous studies, the nanosized PEBBLE matrix 
was made of a polyacrylamide hydrogel, however, in this study the nanoparticles 
were attached with either TAT-Cys, a cell penetrating peptide, or the F3-Cys 
peptide, which facilitates preferential uptake into cancer cells.  One important 
aspect of these sensors was the incorporation of both a sensing dye, G2, and a 
reference dye, Alexa 647 dextran 10,000, or HiLyte 680 SE, which emits in the 
near infrared range (NIR), and thereby increases the tissue penetration depth, 
due to low light absorption and scattering at the NIR region, and also improves 
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the signal to noise ratio due to reduced autofluorescence and photobleaching; 
thus addressing some of the challenges commonly associated with imaging and 
sensing schemes in tissues. 17  
 
1.1.2   Nanoparticle-Mediated Imaging  
Oftentimes, the first steps of diagnosing a disease or disorder involve 
imaging of the tissue or region of interest.   Imaging modes, including X-ray, MRI, 
and ultrasound are routinely used for such purposes; however, these imaging 
modalities are limited in that they cannot provide information on cellular and 
molecular level activity.   Furthermore, these imaging techniques are normally 
used after the disease or disorder has already presented itself clinically and has 
begun to affect the patient’s quality of life.  These shortcomings, along with 
others not detailed here, have opened the door for the development of imaging 
techniques that provide real-time cellular information, i.e. direct visualization of 
biological processes within cells and tissues.  Nanoparticle-mediated imaging is 
one such technique.  There are many appealing properties of nanoparticle-
mediated molecular and cellular imaging, which include early detection, the 
ability to exploit the EPR effect in the case of tumors1, long lasting contrast 
enhancement1, and multiple imaging capabilities within one nanoplatform1,18.  
Also, recent advancements in this branch of research have resulted in the ability 
to design polymeric nanoparticle platforms that bioeliminate naturally from the 
body19, further underscoring the advantages of nanoparticle-mediated imaging.  
Some notable examples of nanoparticle-mediated imaging include photoacoustic 
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20-22, Raman 20,21, dark field 22, computed  tomography and positron emission 
tomography (CT & PET) 23,24, and magnetic resonance imaging (MRI) 20,23 . 
In addition, it is oftentimes quite crucial to perform imaging immediately 
after the administration of therapy, to monitor treatment efficacy, or in the case of 
cancer, to monitor the presence of residual tumor tissue and/or regrowth.   Such 
imaging enables the clinician to monitor the efficacy and/or the need for further 
treatment.  One example in which post-treatment imaging is crucial is exogenous 
cell therapy.   Exogenous cell therapy, the use of transplanted cells to either 
totally replace or rejuvenate diseased cells, is a treatment modality that has been 
developed over the last 50 years. Recently, it has received more attention due to 
advances in stem cell research.  Cell therapy has been utilized in the treatment 
of diseases or injuries associated with the teeth25, central nervous system26, and 
with autoimmune deficiency27.  In order to continue to improve cell therapy 
techniques, applications, and overall efficacy, real time monitoring of the 
transplanted cells is crucial.  Dyes, fluorescent proteins, quantum dots and 
genetic markers have all been utilized for monitoring transplanted cells. 28 
Nanoparticle-mediated imaging, in this instance, has also gained interest 
because of the ability to tailor the nanoparticles for the specific cell line/therapy 
through the choice of matrix, physical properties, and surface characteristics.  A 
review by Xu, et al 29 details the various nanoparticle imaging modalities, 
including fluorescence, MRI, and positron emission tomography, that have been 
successfully utilized in the tracking of implanted cells in animals and humans.  
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Additionally, the inclusion of nanoparticles can be used to strategically 
enhance the sensitivity and effectiveness of the conventional imaging method.  A 
research effort led by Popovtzer30 utilized targeted gold nanoparticles for 
molecular CT imaging of head and neck cancer lines, in conjunction with a 
clinical CT machine.  The study demonstrated that because of the increased X-
ray attenuation by the nanoparticles, the cancer cells to which the nanoparticles 
attached are easily detected and distinguished from noncancerous cells and cells 
that had not been treated with nanoparticles30. This study is an example of how 
the inclusion of nanoparticles can greatly enhance the information clinicians can 
attain without the need of purchasing more equipment or dramatically changing 
the treatment protocol. 
 
1.1.3   Nanoparticle-Mediated Therapy 
In the category of nanoparticle-mediated therapies, targeted drug delivery, 
photothermal, and photodynamic therapies have emerged as particularly 
promising among many other forms. A major advantage of nanoparticle-mediated 
therapy is the ability to selectively target malignant cells while leaving nearby 
healthy cells almost completely unharmed.  Nanoparticle-mediated therapy 
enables a treatment option in which very low overall concentrations of a 
therapeutic agent are administered; however, the accumulation of the agent in 
the target cells is usually much higher than what can be achieved through 
intravenous administration of the drug alone, culminating in a much improved 
treatment efficacy and dramatically decreased rate of unwanted side-effects.   
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The large increase in treatment efficacy is primarily due to the inclusion of the 
therapeutic agent into the nanoparticle matrix, which is generally a targetable, 
biologically compatible, drug delivery vehicle.    To date, nanoparticle-mediated 
therapy has been shown to be effective in addressing oncological 31-33, 
cardiovascular 34-36  and dermatological 37-39 ailments among other diseases.  As 
a result, there continues to be a tremendous amount of interdisciplinary research 
effort driven by the promise of nanoparticle-mediated therapy and the dire need 
to understand the resulting physiological implications of this class of treatments.  
 
1.1.1.a Targeted Drug Delivery 
Targeted drug delivery via nanoparticles provides a treatment option with 
much less probability of unwanted side effects commonly associated with 
exposure to high doses of many drugs. An ideal treatment would improve the 
patient’s standard of living, rather than further compromising their well-being, 
which may be declining due to the disease.  Unfortunately, many of the most 
effective drugs for addressing severe and debilitating conditions also have acute 
side effects. The prospect of harsh side effects may make the decision between 
various treatments difficult.  Chemotherapy, for example, is still one of the most 
widely utilized conventional cancer treatment methods, however, because these 
drugs typically target cells that divide rapidly, a common trait of many cancerous 
cells lines, any healthy cells that also share this trait are harshly damaged.  
According to the American Cancer Society, the most common side effects of 
chemotherapy include: damage to bone marrow, blood, hair follicle, digestive 
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tract, and reproductive tract cells.   One innovative method to avoid these side 
effects is the encapsulation of the chemotherapy drug into a targeted 
nanoparticle matrix, to ensure that healthy cells do not interact with the drug.   
Furthermore, nanoparticle-mediated drug delivery enables the successful 
delivery of drugs to solid tumors by taking advantage of the enhanced 
permeability and retention effect40, as well as of active targeting. Metal, 
polymeric, hybrids of metal and polymeric, and silica nanoparticles, are all 
currently being utilized for targeted chemotherapeutic drug delivery. 1, 32, 33, 41  
Recently, for example, significant work in this area was completed by Liu et al.,32 
in which they describe the development of targeted silica nanoparticles that have 
a hydrophobic anticancer drug, docetaxel attached.  A mixed layer of 
phospholipids served as a coating on the nanoparticles to ensure that the 
docetaxel did not interact with healthy cells.  This particular study is 
representative of the essential benefits of targeted nanoparticle-mediated drug 
delivery, in that the study combines high drug loading, controlled drug release 
(pH), low toxicity and high efficacy in one treatment mode32.  Another recent in 
vivo study, on ovarian cancer, demonstrates how targeted nanoparticles 
delivering the classical chemotherapeutic drug cisplatin work well even on tumors 
that are resistant to the “naked” cisplatin drug.42  
 
1.1.1.b Photothermal Therapy 
 Nanoparticle-mediated photothermal therapy involves the selective 
heating of malignant cells while leaving the neighboring cells intact. Nanoparticle-
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mediated photothermal therapy enables selective extracellular heating of the 
cells by attaching predominantly to the target cells external membranes or 
intracellular heating once the nanoparticle has been taken up within the cell.  
Successful nanoparticle-mediated photothermal therapy has been demonstrated 
with a variety of different types of nanoparticle matrices, encouraging continuous 
research efforts and applications. 43,44  Nanoparticle-mediated photothermal 
therapy is especially well suited for treating cancer due to the increased heat 
sensitivity associated with cancer cells, as well as a tumor’s inability to efficiently 
dissipate heat as a result of the poor vasculature networks.  Nanoparticle-
mediated photothermal therapy has been used widely as both a primary mode of 
treatment as well as a preliminary treatment to weaken otherwise resistant cells 
to more conventional therapies.17, 18, 43, 45  
 
1.1.1.c Photodynamic Therapy 
 Another emerging form of nanoparticle-mediated treatment is 
photodynamic therapy.  Much like the previously discussed therapies, the need 
to encapsulate the therapeutic agent, in this case a photosensitizer, inside of a 
dynamic carrier is also of importance because many of the most widely used 
photosensitizers are hydrophobic and very susceptible to reduction into an 
inactive chemical form if administered intravenously. Furthermore, targeted 
delivery is also crucial to ensure that the reactive oxygen species that are 
produced following the excitation of the photosensitizer do not harm healthy cells.   
Many nanoparticle matrices have been utilized in photodynamic therapy studies 
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including ceramic, hydrogel, polymer/metal hybrid, and silica  1, 46 -50  A recent 
study conducted by Rojnik, et al 51, characterized the performance of FDA 
approved, PEGylatd poly-(D,L-lactide-co-glycolide) nanoparticles loaded with an 
extremely potent photosensitizer, temporfin in both in vitro and in vivo studies.  
The researchers demonstrated that controlled release of the photosensitizer to 
target cells could successfully be controlled, via the modification of the 
nanoparticles’ composition, pore size, and surfaces.  Additionally, the study 
demonstrated that the incorporation of the photosensitizer into the nanoparticle 
matrix resulted in an increase in photodynamic effectiveness in vitro when 
compared to its administration in a standard solution and an advantageous 
distribution throughout the tumors in the in vivo studies. 51  
 
1.2 Overview of This Dissertation 
Chapter 2 of this dissertation describes the first ever use of Coomassie 
Brilliant Blue G-250 dye as therapeutic agent for photothermal therapy.  
Coomassie blue dye has various desirable qualities.  It is a derivative of the 
commonly used food coloring Blue No. 1 and is nontoxic to healthy animals at 
very high concentrations.  The dye also has a very high molar absorption 
coefficient at 600nm and nearly no fluorescence quantum yield.  Taken together, 
Coomassie blue dye is an ideal candidate for use as a photothermal therapy 
agent as it can be utilized at high concentrations to absorb strongly in the 
therapeutic window (wavelengths ranging from 600-1000nm) and reradiate the 
absorbed energy predominately in the form of heat to the surrounding 
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environment.  Chapter 2 details a study in which the dye has been covalently 
linked into a polyacrylamide nanoparticle matrix and utilized in in vitro 
experiments with HeLa cells.  This study establishes a third mode of application 
for this specific type of nanoparticles as they have also been used successfully in 
visual delineation 2,52-54 and photoacoustic imaging studies18 of brain tumors, 
previously performed in the Kopelman lab.   
Chapter 3 details the optimization of gold nanoparticles, fabricated using 
femtosecond laser ablation, for nuclear delivery into HeLa cells.  Among the large 
variety of subcellular organelles, the nucleus remains a significant target for 
nanoparticle research, i.e. investigations of potential diagnostic and therapeutic 
applications, due mostly to the genetic information and transcription machinery, 
which reside there.  Gold nanoparticles manufactured via laser ablation of a bulk 
gold in ultra pure water yields so called “virgin surfaces” devoid of any unreacted 
chemical molecules, as is the case of chemical, wet lab techniques for producing 
gold nanoparticles.  These virgin surfaces enable the optimization for intracellular 
and subsequent nuclear delivery through the addition of peptides.  In the study 
outlined in Chapter 3, two peptides, RGD & NLS, were attached to the 
nanoparticles and successful, efficient nuclear delivery was achieved using a 
nanoparticle concentration of only 100pM. 
Some forms of gold nanoparticle-mediated photothermal therapy are 
advantageous over other forms of nanoparticle-mediated photothermal therapy, 
due to their ability to take advantage of the “therapeutic window” in which one 
utilizes near-infrared (NIR) radiation to excite the Au NPs and induce thermolysis 
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in cells.  Single gold nanoparticles have a maximum absorption in the range of 
520-560nm.  When irradiated at these wavelengths, the electrons are 
photoexcited and they vibrate, which in turn produces heat.  This heat production 
is exploited in gold nanoparticle mediated photothermal therapy. The localized 
heating due to the nanoparticles within the cell leads to hyperthermia, 
photothermal lysis and cell death.  Photothermal therapy proved to be an 
attractive alternative to conventional treatments for many reasons; one of the 
most important reasons is that cancer cells are known to be more heat sensitive 
than normal, healthy cells.  Despite several successful experimental 
demonstrations of this technique, a complete theoretical treatment did not 
emerge until much later.  Khlebtsov, et al describe the temperature change due 
to irradiating solid, single gold nanoparticles, as well as various types of clusters.  
A brief summary for single gold nanoparticle follows; a more detailed treatment is 
given in Chapter 4.  The change in temperature as a result of heating a single 
gold nanoparticle in water can be described as follows,  
 
     ∆! = !!!!!"#!"               Eqn. 1.1 
 
where <F> is the average laser fluence, Cabs is the absorption cross section, m is 
the mass of the gold nanoparticle, and κ is the specific heat of gold, and r is the 
radius of the nanoparticle.  If the dimensionless quantity, Qabs, is defined as the 
normalized absorption cross-section and use the density of gold, ρ, Eqn. 1.1 can 
be rewritten as: 
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     Δ! = !!!!!"#!"#                      Eqn. 1.2 
 
 The fraction of Cabs/m or  Qabs/r determine the heating and therefore the 
efficiency with which one can kill the cell.  These fractions explain the reason that 
gold nanorod-mediated photothermal therapy is more effective in some respects.  
However, it is important to note that this method has drawbacks including 
increased dark toxicity, and occasional changes in nanoparticle morphology due 
to melting and thermal stress, which results in a shift of the absorption spectrum.   
 Encouraged by the results of the previous study, the same nanoparticles 
described in Chapter 3 were utilized for photothermal therapy of HeLa cells. 
Chapter 4 is a comparative study of the efficacy of photothermal therapy when 
treatment is mediated by gold nanoparticles located predominantly within the 
nucleus in contrast to when the Au NPs are predominantly in the cytoplasm.  The 
advantages of directly heating the nuclei of the cancer cells are numerous, 
including the smaller target volume, lower heat capacity and increased likelihood 
of causing irreparable damage to the cell’s DNA (located in nucleus).  
Furthermore, it is likely that nucleus specific PTT will induce notable differences 
in the mechanisms through which the cancer cell dies, which will provide 
invaluable insight for in vivo treatment planning.  Chapter 4 describes a 
systematic study of the difference in PTT efficacy over short- and long-term time 
periods when the Au NPs are targeted and efficiently delivered to the cancer cell 
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nuclei as well as some discussion of the pathways throughout the cells die in 
both scenarios.    
 16 
1.3 Figures 
 
 
 
                   
 
 
 
 
 
 
Figure 1.1:  Schematics PEBBLE sensors 55 : (A) Single core NP loaded with 
both sensing and reference components), (B) Core–shell PEBBLE (core–shell 
NPs with spatially separated sensing and reference components), (C) 
Temperature-sensitive NP PEBBLE (NP matrix as a sensing unit).  PEBBLE-
mediated studies 8 17 : (D) Intracellular Ca2+  and (E) oxygen sensing.  
E D 
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Chapter 2 Photothermal Therapy of Cancer Cells Mediated by Blue 
Hydrogel Nanoparticles 
 
 
Some of the material in this chapter has been adapted with minor modifications 
from the following article, which has been accepted for publication:  
 
Curry, T., Epstein, T., Smith, R., & Kopelman, R. Photothermal Therapy of 
Cancer Cells mediated by Blue Hydrogel Nanoparticles.  Nanomedicine, (2012). 
Accepted for publication 
 
 
2.1  Introduction  
Cancer is still one of the leading causes of death in America; in 2010, 
1,596,670 new cases and 571,950 cancer-related deaths were projected to 
occur1. To address this challenge, many advances have been made in the early 
detection and treatment, directly resulting in an increase in the treatment options 
available including chemotherapy, radiation treatment, and surgical removal. 
Despite these advances, cancer treatment has continued to be a hotbed of 
research because in many instances treatment plans must be robust to address 
the issues of probable damage to surrounding healthy tissues, tumor regrowth, 
and a decrease in the quality of life for the patient.  In recent years many groups 
have devoted their efforts toward employing nanoparticle (NP) platforms for 
detecting and treating various types of cancer.   Nanoparticles are advantageous 
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because they are minimally invasive, have tunable characteristics (i.e. size, 
absorption, surface charge), and can be used as targeted, multifunctional, or 
combined treatment platforms2-4.  To date, nanoparticles have been used as 
contrast agents for the detection and imaging of cancerous cells, both in vitro and 
in vivo, coupled with photosynthesizing dyes for photodynamic therapy, or 
combined with chemotherapy drugs to facilitate cell specific drug delivery, as well 
as coupled with external magnetic fields to induce cell death via hyperthermia2-10.   
Photothermal therapy (PTT) mediated by nanoparticles has emerged as a 
promising cancer treatment modality that has been used to treat various 
cancerous cell lines. Gold, silver, iron oxide, and magnetite are some of the 
materials that have been used in nanoparticle mediated PTT10-13.  Of these, the 
use of gold nanoparticles has seemingly emerged as the frontrunner in PTT 
research and various groups have created experimental protocols that yield a 
large variety in the gold nanoparticle structures, including nanorods, triangles, 
pyramids, and shells10,12.  Many groups utilize NIR radiation to excite the gold 
nanoparticles and induce thermolysis in cells, taking advantage of the low 
absorption and scattering of the radiation by tissues at these wavelengths.  
Despite these advantages, there have been many studies conducted exploring 
the origins and levels of cytotoxicity of many types of gold nanostructures, with 
apparently conflicting conclusions regarding their use8,14,15. This, and other 
considerations (see below), may be opening the door for assessing the potential 
of another PTT modality aimed at a widespread use in the treatment of various 
malignant cancers. Notably, polymeric nanoparticles have been FDA approved 
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for clinical studies due to their apparent high therapeutic factor16. In particular, 
much research has been done on biocompatible, biodegradable, and bio-
eliminable hydrogel nanoparticle platforms3,4. Incorporated for this study is the 
FDA approved dye, Coomassie blue. 
In this study we investigate the utility of biologically compatible hydrogel 
nanoparticles, which have Coomassie blue (CB) dye covalently linked into their 
polyacrylamide (PAA) matrix, called here CB-PAA, as candidates for 
photothermal therapy (PTT) of cancer cells in vitro. We substantiated the 
capability of the CB-PAA nanoparticles to serve as a platform for a multimodal 
therapeutic approach (photoacoustic imaging20, visual surgical delineation17-19, 
and now PTT). Nanoparticles of this type have previously been used in our lab 
for targeted in vivo photodynamic therapy (with photosensitizers such as 
methylene blue), combined with MRI and EPR contrast enhancement agents, as 
well as for photoacoustic structural imaging and for the delineation of glioma 
boundaries (in the latter two cases with CB-PAA NPs, detailed in the background 
section), and have also been shown to be non-toxic, targetable, biodegradable 
and bio-eliminable17-20. Thus, with the here demonstrated use for PTT, such CB-
PAA NPs would be utilizable in three different ways, even simultaneously, i.e. tri-
functional, to which can easily be added targetability.  
The simplicity of the method described here goes beyond the use of 
existing nano-platforms. The excitation source employed in this study is an 
inexpensive, portable LED array with a maximum emission at 590 nm.  Based on 
its use we find that CB-PAA mediated PTT of HeLa cells, incubated with 1.2 
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mg/mL of nanoparticles for 24 hours, yields nearly complete cell death, within 1 
hour of treatment, after 40 minutes of illumination.  Moreover, cells that were 
incubated for 24 hours with only 0.6mg/mL of the nanoparticles, and with only 20 
minutes of illumination, yielded nearly complete cell death 3 hours after 
treatment. On the other hand, under identical illumination, but without 
incorporation of the dye, there is little cell kill. Likewise, with no illumination, but 
with the dye containing NPs, there is insignificant cell kill. This promises, for in-
vivo use, an extremely high selectivity of cell death, based on combined immuno 
and “illumo” targeting, with minimal side effects. Overall, we find that CB-PAA 
mediated PTT is characterized by high efficacy, with much promise for inclusion 
in a multi-pronged and safe approach for treating various types of cancers.  
 
2.1.1   Background 
 As previously mentioned, CB-PAA nanoparticles were utilized in two 
previous studies.  The first study19 detailed: 1) the development of a derivatized 
CB-APMA—an acrylamide terminated form of the commercially available CB 
dye, 2) the preparation of covalently linked CB-PAA using the crosslinkable CB 
derivative, and 3) surface modification of the CB-PAA nanoparticles with 
polyethylene glycol (PEG) and F3 peptide for improved biostability and 
decreased nonspecific binding.  The development and incorporation of the 
crosslinkable CB derivative into the PAA nanoparticle matrix resulted in high dye 
loading efficiency (ca. 70 % of the input amount of CB), which is lower than PAA 
nanoparticles post-loaded with CB dye (ca. 90%), but much higher than the PAA 
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nanoparticles with encapsulated CB dye (ca. 5%). Dye leaching experiments 
conducted under simulated physiological conditions demonstrated that the CB-
PAA nanoparticles were by far the best candidates for the delineation studies as 
no dye leaching was detected.  On the other hand, between 50-70% of the CB 
dye leached out of the post-loaded nanoparticles within 2 hours.  In vitro staining 
experiments conducted with targeted nanoparticles on 9L gliosarcoma cells 
demonstrated effective cell staining, while the blue color from the non-targeted 
cells was negligible.  In vivo tumor delineation studies were conducted using rat 
BTW models with implanted 9L gliosarcomas and cranial windows.  Rats treated 
with targeted, CB-PAA showed the increasing and longer lasting visual 
delineation (with no additional lighting, or optical aid required) up to 2 hours in 
comparison to the nanoparticles with CB post-loaded and encapsulated within 
the matrices. 
 The second study20 involved the use of the surgically removed rat brains 
for photoacoustic imaging of the implanted tumors ex vivo.  For imaging 
purposes, two brains from rats that were treated with different nanoparticle 
concentrations (250 mg/Kg and 125mg/Kg) and a control brain (no treatment), 
were placed together and imaged simultaneously.  The tumor from the rat that 
was treated with the highest concentration of nanoparticles was clearly visible to 
the eye; however, the tumor from the rat that was treated with the lower 
nanoparticle concentration was not distinguishable from the surrounding healthy 
tissue.  The photoacoustic image generated by the nanoparticles enabled 
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observation of both tumors and the control brain could not be seen in the image.  
The first two prongs of the multimodal, therapeutic approach was established in  
 
2.2  Materials and Methods 
2.2.1 Materials 
Coomassie blue G (CB), acrylamide (AA), ammonium persulfate (APS), 
N,N,N’,N’-tetramethylethylenediamine (TEMED), sodium dioctyl sulfosuccinate 
(AOT), Brij 30, N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), and 
3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) were 
purchased from Sigma Aldrich. Dulbecco’s Modified Eagle medium (DMEM 1195 
& 21063), Dulbecco’s Phosphate Buffered Saline (DPBS), Rosewell Park 
Memorial Institute medium (RPMI-1640), fetal bovine serum (FBS), and 
penicillin-streptomycin glutamine, Live/Dead Baclight Bacterial Viability Kit, were 
all purchased from Invitrogen.  N-(3-Aminopropyl) methacrylamide hydrochloride 
(APMA) was purchased from Polysciences Inc. Ethanol (95%), and hexane were 
purchased from Fisher Scientific. Phosphate buffered saline (PBS) solution (pH 
7.4) was made with phosphate buffered saline tablet from Sigma Aldrich. 
100mm, 35mm, and 96-well microplates were purchased from BD Biosciences. 
The water used throughout the experiment was deionized (DI) water, purified by 
a Milli-Q system from Millipore Co.  
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2.2.2 Light Source 
The excitation source employed for the PTT experiments is a low intensity 
LED array created with an emission peak of 590nm.  The array was fabricated in 
house as follows: an array of 256 wide angle LEDs from Kingbright Corporation 
were soldered to a fiberglass PCB board; wide angle LEDs and mirrors were 
then attached around the perimeter of the array to increase illumination 
uniformity, and lastly, an adjustable power supply was connected to the setup to 
enable control of the power output of the LED array.  The intensity of the array is 
25.4 mW/cm2 and the deviation in irradiance at the face of the mirrors was found 
to be 6.2%.  
 
2.2.3 Cell Culture 
HeLa 229 cells  (American Type Culture Collection) were grown in 
Dulbecco’s modified Eagle medium (DMEM 11995) supplemented with 10% fetal 
bovine serum (FBS) and 1% penicillin-streptomycin at 37°C and 5% CO2 in a 
humidified incubator.  Cells were plated and grown in 100mm petri dishes for the 
cellular uptake assay, in 96 well plates for the MTT assay, and in 35mm petri 
dishes for the photothermal therapy tests. 
 
2.2.4 Nanoparticle Synthesis & Characterization 
2.2.4a  Synthesis 
The CB-PAA used in this study were synthesized according to a protocol 
established in a previous study completed in our group17, and modified slightly 
 34 
using the Coomassie blue derivative as the only cross-linker. Briefly, the 
Coomassie blue (CB) covalently linked polyacrylamide (PAA) nanoparticles were 
prepared by a reverse microemulsion polymerization method. A monomer 
solution was prepared by dissolving monomers, acrylamide (610 mg) and APMA 
(40mg), in 1.2mL of water. A dye solution was prepared by dissolving 165 mg of 
CB linked APMA in 0.8 mL of DMF and then 0.4-1.0mL of Brij 30 was added to 
the dye solution.  The monomer and dye solutions were mixed and sonicated to 
make a homogeneous solution. The solution was then added to a deoxygenated 
hexane (60mL) that contained two surfactants, AOT (4.8 g) and Brij 30 (total 
amount of 9.5 mL). After stirring the mixture under inert atmosphere for 20 min, a 
freshly prepared 66% (w/v) APS solution (400 µL) and TEMED (200 µL) were 
added to the mixture solution to initiate polymerization. The solution was then 
stirred under inert atmosphere at room temperature for 1.5 hours. After 
completing the polymerization, hexane was removed with a Büch RII rotary 
evaporator and the residue was then suspended in ethanol. The suspension was 
then washed in an Amicon filtration system (Millipore Co.) with a 300,000 NMWL 
Millipore ultrafiltration membrane under 10-20 psi of pressure with ethanol 10 
times followed by 10 water washes to ensure all surfactants and unreacted 
molecules were removed.  The nanoparticle solution was then filtered through a 
0.22 Whatman syringe filter.  The resultant CB-PAA nanoparticles were freeze-
dried and stored at room temperature in a Thermo Electron Corp ModulyoD 
freeze dryer for later use. 
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Blank PAA NPs were fabricated using the procedure outlined in a previous 
study conducted by our group17. Briefly, the blank PAA nanoparticles were also 
prepared by a reverse microemulsion polymerization method. A monomer 
solution was prepared by dissolving monomers, acrylamide (711 mg) and APMA 
(55 mg), in 1.6 mL of DPBS. GDMA (470 µL) was added to the monomer solution 
and then the mixture was stirred and sonicated to make a homogeneous 
solution. The monomer solution was added to a deoxygenated hexane (45 mL) 
that had been previously mixed with two surfactants, AOT (1.6 g) and Brij 30 (3.3 
mL).  The mixture was stirred under an inert atmosphere for at least 20 minutes, 
after which the initiators, 10% (w/v) APS solution (100 µL) and TEMED (100 µL), 
were added to begin polymerization. The solution was stirred under inert 
atmosphere at room temperature for at least 2 hours. The remaining hexane was 
removed with the rotary evaporator and ethanol was added to form a residue. 
The suspension was washed in an Amicon filtration system (Millipore) with a 300 
kDa filter membrane under 10-20 psi of pressure with ethanol 5 times and with 
water 5 times, during which all surfactants and unreacted molecules were 
removed from the product. The resultant CB-PAA nanoparticles were freeze-
dried and stored for later use. 
 
2.2.4a  Characterization 
CB-PAA NPs were dissolved in DPBS, syringe filtered  (Whatman, 0.2µm 
pore size) and diluted to 0.05 mg/mL, after which the size and zeta potential of 
nanoparticles were measured using a DelsaNano DLS particle sizer (Beckman 
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Coulter, Brea, CA). Representative sizing and zeta potential data is shown in 
Figure 2.1. The percent of Coomassie Blue dye in each batch of nanoparticles 
was calculated, based on a standard calibration curve of the dye’s absorption at 
597nm.  Two batches of NPs were used; the NPs used in the MTT assays and 
PTT experiments had 8.5% Coomassie Blue dye loading and NPs used for 
cellular uptake experiments had 11% dye loading. 
 The degree of photobleaching of the CB-PAA NP during PTT was 
determined by first measuring the absorbance of varying concentrations (0.1, 0.6, 
& 1.0 mg/mL) of CB-PAA dissolved in DPBS using UV-VIS spectrometry and 
then illuminating the samples for 40 minutes.   The absorbance was again 
measured immediately following illumination. The degree of photobleaching was 
quantified as the percent difference in absorbance at 600nm before and after 
illumination.  The absorbance of the CB-PAA NPs decreased a maximum of 40% 
after 40 minutes of illumination for all of the concentrations as shown in Figure 
2.2.  
To investigate if CB dye degrades out of the nanoparticle matrix during 
illumination the following tests was completed: CB-PAA NPs were dissolved in 
DPBS, illuminated continuously for 40 minutes and then filtered using a 
Whatman syringe filter (0.02 µm pore size) before the absorbance spectra was 
measured.  As demonstrated by the large difference in the absorbance peaks, 
very little of the CB is degraded from the nanoparticles during illumination (Figure 
2.3).  Furthermore, for higher CB-PAA NP concentrations, it is likely that the very 
small absorbance peak of the filtrate is due to a small amount of nanoparticles 
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that were able to pass through the filter. We estimate the leaching to be well 
below 1%. 
Singlet oxygen production during illumination of the CB-PAA was 
measured to ensure that singlet oxygen production did not contribute to CB-PAA 
nanoparticle induced cell kill.  2mL of a CB-PAA NP solution with a concentration 
of 0.6 mg/mL was thoroughly mixed with 80 µL or a 100µM stock solution of 
ADPA dissolved in DPBS.  The solution was placed in a cuvette and irradiated at 
600nm using an ozone-free xenon-arc lamp (150@, Jobin Yvon Horiba, slit width 
10nm) while being constantly stirred at a moderate speed to ensure uniform 
suspension and oxygen diffusion. ADPA was excited at 378nm and the 
fluorescence measured at different time points over 10 minutes.  The calculated 
k value for the CB-PAA NPs was 5 x 10-5 s-1 (Figure 2.4). Considering 
photobleaching of the ADPA, this indicates that the singlet oxygen production of 
the CB-PAA NPs is at least an order of magnitude lower than that of the 
nanoparticles conjugated with Methylene blue (9.4 x 10-4 s-1), Photofrin (14 x 10-4 
s-1), and HPPH (1.23 x 10-4 s-1), which are all photosensitizers routinely used in 
our lab for PDT5,7,28. 
The temperature change due heating caused by the CB-PAA NP alone in 
solution was measured by dissolving the NPs in DPBS at different concentrations 
and then illuminating the solution 40 minutes in a small petri dish.  The 
temperature of the solution was monitored the entire duration of the illumination 
using a thermocouple that was attached to the middle of the plate and was 
recorded every four minutes.  The measurements were carried out inside of a 
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humidified incubator at 37°. Two conditions were tested, the first with the 
temperature of the nanoparticle solution was approximately room temperature 
and the second where the solution was very near 37° before illumination began.  
The change in the temperature of the nanoparticle solution (ΔT) during the 
illumination time is shown in Figure 2.5. 
 
2.2.4c CB-PAA Nanoparticle Solution Calibration 
A known amount of previously freeze dried CB-PAA were dissolved in 
fresh DPBS (14040) to make a stock solution.  The stock solution was then used 
to make diluted concentrations of CB-PAA solutions between 0.01-0.35mg/mL in 
DPBS with total volume of 1.5 mL each.  The absorbance of dilute nanoparticle 
solutions was measured using Shimadzu UV-1601 Spectrophotometer; a 
representative plot is shown in Figure 2.6.   A calibration curve relating CB-PAA 
NP concentration to absorbance at 600nm was constructed and fit linearly. The 
CB-PAA stock solution was then filtered using a 0.2 µm Whatman syringe filter; a 
small sample was taken and diluted to a concentration between 0.01-0.35mg/mL 
and the absorbance measured.  The linear calibration curve was then used to 
extract the new concentration of the filtered nanoparticles.  Losses due to filtering 
ranged between 0 – 30% depending on the amount of time the nanoparticles had 
been stored.  
 
2.2.4d Cytotoxicity of the CB-PAA Nanoparticles  
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Cytotoxicity of the CB-PAA nanoparticles was tested with a standard MTT 
cell viability assay examining metabolically activity; cells that had not been 
incubated with any nanoparticles were used as a control. Cells were plated on a 
96-well plate with a cell density of 5000 cells/well and cultivated overnight. CB-
PAA nanoparticles and growth media were added into the wells so as to achieve 
for each sample an overall concentration ranging between 0.1-1.2 mg/mL and 
then incubated with the cells for 24 hours. The cells were then carefully washed 
and 200 µL of clear growth media plus MTT reagent were added (20µL of 
5mg/mL of the MTT reagent dissolved in the 180 µL of media without FBS).  After 
4 hours, 200 µL of DMSO was added into each well, so as to solubilize the 
formazan crystals produced from the MTT in viable cells. The 96 well plates were 
covered with aluminum foil and placed on a rocking shaker (Reliable Scientific, 
Inc) and allowed to gently mix overnight in the dark.  Absorption at 550 nm was 
measured, for each well, with a Molecular Devices Spectramax Plus 384 plate 
reader. The results from 24 wells for each nanoparticle concentration were 
analyzed. Coomassie blue dye related toxicity was not investigated in this study 
as no measurable toxicity was found in any of the previous studies completed in 
our group17-20 and CB has been successfully utilized in both laboratory and 
clinical studies at concentrations much higher (10 and 20 fold) than those used in 
the present study21,22.   
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2.2.5 Cellular Uptake Assay  
Cells were grown to at least 90% confluency, passaged, and replated with 
half the initial concentration of cells.  The cells were then allowed to reattach and 
grow overnight.  Varying amounts of CB-PAA NP stock solution was mixed with 
growth media to achieve concentrations ranging between 0.1-1.2 mg/mL of 
particles in a total of 3mL of solution.  After 24 hours, the cells were washed 
twice with DPBS and the particle solutions + media was added to the cells.  The 
cells were allowed to incubate with the nanoparticle + media solution for 24 
hours, then again washed twice with DPBS to remove free nanoparticles, 
trypsinized, and centrifuged for 5 minutes at 900 RPM. Trypsin, media and DPBS 
were aspirated, then 1.5 mL DPBS was added to the cells. 300µL of lysing 
reagent (Thermo Scientific, M-PER Mammalian Protein Extraction Reagent) was 
then added to each.  For reference, cells that had been allowed to grow for the 
same amount of time without CB-PAA NP, were counted and adjusted so that 
their concentrations matched those of the cells incubated with particles. After 
24hrs, the absorbance at 600nm was measured for the cells with CB-PAA, i.e. 
the amount of absorbance from the CB-PAA in the cells was measured using 
UV-VIS spectrometry with lysed reference cells. The spectra were then analyzed 
using a least squares method; the NP concentration, CNP, was extracted by fitting 
the absorption spectrum to the linear combination:  
 ! ∙ !"#!"# + !!" ∙ !"#!" + !"#$% 
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where SPCref is the absorption spectrum of the lysed cells without NPs and 
SPCNP is the absorption spectrum of NP solution in DI water.  R and CNP are the 
fitting parameters.   The absorbance of the CB-PAA only was extracted from the 
analysis and converted to the corresponding concentration in mg/mL and then 
divided by the number of cells to get the average CB-PAA per cell. 
 
2.2.6 Photothermal Therapy & Live/Dead Assay 
CB-PAA nanoparticles dissolved in DPBS were mixed thoroughly with 
fresh growth media, added to cells and then allowed to incubate for 24 hours.  
The cells were washed twice with DPBS to remove any nanoparticles remaining 
outside of the cells, and new clear growth media was added (DMEM 21063).  
5µL of 1.5 mM of Propidium Iodide dissolved in DMSO and 1µL of 2 mM of 
Calcein AM dissolved in DMSO was added to the cells and allowed to incubate 
for at least 10 minutes.  Baseline measurements for the PTT were performed on 
an Olympus IX71 inverted microscope (Olympus America Inc., Melville, NY) 
using a 20x objective. The cells were then placed under the light source, for 10, 
20 or 40 minutes, inside an incubator at 37° C and then immediately imaged 
following the treatment.  The cells were then placed back in the incubator and 
only taken out for imaging at thirty-minute intervals for another 3 hours.  The 
images were analyzed using Image J software to determine the number of live or 
dead cells per image, with the presence of Calcein AM fluorescence, indicating a 
live cell, and propidium iodide fluorescence in the nucleus indicating a dead cell 
(Figure 2.7).  
 42 
 
2.2.7 Controls 
Blank PAA NP in cells: Dried, blank PAA NPs were resuspended in 
DPBS and syringed filtered with a 0.2µm Whatman filter.  Cells were incubated 
with 1.2mg/mL of blank PAA NPs solution for 24 hours and then washed 
thoroughly to remove any nanoparticles remaining outside of the cells.  The cells 
were then illuminated for 40 minutes using the light source, after which the 
degree of cell death was quantified with the live/dead cell assay. 
No NPs in cells: In order to investigate possible cell death caused by 
heating due to the light source alone, cells that had not been incubated with any 
NPs were illuminated with the light source continuously for 40 minutes.  The 
degree of cell death over time after illumination was quantified with the live/dead 
cell assay. 
 
2.3  Results & Discussion 
2.3.1 Cytotoxicity 
Many hydrogels, including PAA, have been used extensively in vivo, with 
no major toxic effects4,24.  Furthermore, they are very flexible in their molecular 
engineerability, i.e. they can be modified for controlled, fast or slow, 
biodegradation.  Nanoparticles of this type can also be optimized towards fast or 
slow dye delivery.  Oftentimes, the NPS are PEGylated for controlled circulation 
time, and can be easily surface derivatized with molecular targeting moieties, e.g. 
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peptides or aptamers, to achieve high specificity to certain cancer cells4,23.  
Radiolabled, pharmokinetic studies have been conducted on PAA NPs with, and 
without, the biodegradable crosslinker in the NP matrix. In the case of NPs 
without the biodegradable crosslinker, the NPs have “shown tissue distributions 
of the PAA nanoparticles in the reticular endothelial systems that are consistent 
with other nanoparticle studies”4. No adverse effects were found when NPs with 
the biodegradable crosslinkers were utilized up to 90 days post treatment4,6,23,24. 
As shown in Figure 2.8, there was no significant difference in cell viability 
among cells incubated for 24 hours with CB-PAA with concentrations ranging 
between 0.1 and 1.2 mg/mL and the control (no nanoparticles) indicating the 
absence of any measurable dark toxicity associated with the nanoparticles.  We 
note that the nanoparticles stay inside the cells, and that the cancer cells used in 
the present study divide after approximately 24 hours (the normal cell division 
being another indicator of the non-toxicity of these NPs in the dark).   We also 
note that in potential medical applications, the effectivity of the nanoparticles after 
long times is irrelevant because the patient would not have to wait much longer 
than 24 hours between administration of the NPs and the treatment.  
Furthermore, cytotoxicity due to dye leaching was not investigated in the present 
study because dye leaching of CB-PAA NPs was investigated and quantized in a 
previous study and published work completed in our group.  The study was 
conducted under simulated physiological conditions and demonstrated that the 
“covalent linkage of the CB molecule to the NP matrix polymer backbone 
completely eliminates dye leaching.”19 
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2.3.2 Cellular Uptake 
As shown in Figure 2.9, the average amount of CB-PAA nanoparticles 
taken up by the cells increases with increasing NP concentration until 0.4mg/mL, 
after which the uptake of nanoparticles into the cells increases only moderately 
nearing saturation.  These results are similar to findings from studies on the 
uptake of targeted gold and iron oxide hybrid nanoparticles11 and chitosan-
coated silver nanoparticles by two colorectal cancer cells13.  PAA NPs can be 
targeted with the addition of targeting peptides, usually F3 or TAT, via simple wet 
lab techniques.  Multiple cell lines have been successfully targeted using PAA 
nanoparticles5,17,20,25.  Specifically, the addition of targeting moieties to the CB-
PAA has been shown to require shorter incubation times and result in preferential 
uptake in cancerous cells, versus non-targeted NP17,18.  Thus, the targetability of 
the CB-PAA NPs would enable further optimization of this mode of PTT through 
the likely decrease in the required nanoparticle concentration necessary for 
inducing thermolysis.  The present study was a proof of principle study 
completed in vitro, so cell specific targeting was unnecessary at this initial step.   
 
2.3.3 Photothermal Therapy 
Nanoparticle concentration effects: The survival rate (over time) of cells 
that had been incubated with CB-PAA NP ranging from 0.2-1.2 mg/mL, and 
illuminated for 20 minutes is depicted in Figure 2.10. Cells that had been 
incubated with CB-PAA concentrations of 0.2-0.8 mg/mL experienced little to no 
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cell death during treatment; however, cells treated with the highest concentration 
of CB-PAA exhibited a survival rate of only 70% when imaged immediately after 
treatment.  Furthermore, 1.5 hours post-treatment, more than 90% cell death was 
observed for the cells incubated with 1.2 mg/mL of CB-PAA.  Nearly complete 
cell death was also observed 3 hours post-treatment for cells incubated with 0.6 
and 0.8 mg/mL of CB-PAA.  Cells treated with 0.2 and 0.4 mg/mL experienced 
only 22 and 33% cell death, respectively, 3 hours post-treatment.  Interestingly, 
increasing the CB-PAA concentration from 0.4 to 0.6 mg/mL resulted in the 
observation of a particularly dramatic 14-fold increase in cell death after 3 hours. 
As a control, cells were incubated with 1.2 mg/mL of bank polyacrylamide 
nanoparticles without dye and illuminated for 40 minutes. The efficacy of the 
photothermal therapy increases with increasing nanoparticle concentration 
despite the notably smaller increase of uptake CB-PAA after 0.4 mg/mL.  This 
somewhat surprising result may suggest a threshold beyond which changes in 
intracellular nanoparticle distribution cause a more efficient local thermolysis 
although, on average, the overall nanoparticle uptake increases very slightly. 
This is under further study.   
Illumination time effects: Cell viability as function of exposure time of 
cells that had been incubated with 0.6 mg/mL CB-PAA NP and illuminated for 10, 
20, and 40 minutes, is shown in Figure 2.11. 10 minutes of PTT yielded a death 
rate of only about 20% of the cells at 3 hours post-treatment; however, when the 
irradiation time was doubled, the efficacy of the photothermal therapy increased 
dramatically, yielding a 95% cell death at 3 hours post-treatment. When the PTT 
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treatment time is increased even further to 40 minutes, only 35% of the cells 
survived the treatment and complete cell death is observed at one hour post-
treatment.  Control experiments, where cells incubated with 1.2 mg/mL of blank 
PAA NP for 24 hours and irradiated for 40 minutes exhibited only 5% in cell 
death 3 hours post-treatment. This suggests that the major impetus of 
thermolysis induced cell death is the intracellular heating due to the covalently 
linked CB-PAA and not local or external heating due to the light source or any 
scattering effects.   
 
2.4   Conclusions 
The present work is a proof of principle study, which establishes the 
feasibility of a third modality, photothermal therapy, of the CB-PAA NPs.  These 
nanoparticles have been successfully used for both surgical delineation and 
photoacoustic imaging17-20.  Although Poly(acrylamide) gel is not FDA approved 
for use in nanoparticle mediated  PTT of cancer cells, it has been successfully 
utilized in in vivo and in vitro studies for many years.  PAA has also been used 
successfully in implants in animal models24,26.  The pharmacokinetics, 
biodistribution, bioelimination, and toxicity of PAA gel nanoparticles have been 
studied in vivo and no acute toxicity has been associated with potentially 
therapeutic doses4,26-28. 
In the present study, the covalently-linked Coomassie blue polyacrylamide 
nanoparticles have been shown to be very effective in causing PTT induced 
thermolysis in HeLa cells for varying nanoparticle concentrations and treatment 
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times. This study can be used as demonstration that after the CB NPs are used 
to delineate a tumor and the majority of it is surgically excised, any remaining 
cancerous tissues can be located and destroyed by exploiting the photoacoustic 
imaging and photothermal therapy modalities without a need for another NP 
administration. Note that during or right after surgical debulking, any wavelength 
light source can be easily directed at the tumor residues. In vivo studies will 
follow. For optimal future use in in vivo studies, the nontoxic CB-PAA NPs used 
in this study can be further optimized, to be targeted and biodegradable, as was 
demonstrated before with PAA NPs4. 
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2.6  Figures 
 
Figure 2.1:  Size and zeta potential characterization of the CB-PAA NP was 
carried out using a Delsa Nano DLS particle sizer.  CB-PAA NP are 80-95nm in 
diameter and have a zeta potential of 25-27mV.  
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Figure 2.2: Photobleaching of various concentrations of CB-PAA nanoparticle 
solutions.  The degree of photobleaching was quantified as the percent 
difference in absorbance at 600nm before and after illumination.  Error bars 
denote standard error, n=2.  
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Figure 2.3:  Absorbance spectra of the filtrate of varying concentrations of CB-
PAA NP solutions after 40 minutes illumination.  The absorbance spectrum of 
0.1mg/mL of CB-PAA NPs is also displayed for reference. 
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Figure 2.4:  Top-Fluorescence spectra of ADPA in a mixed solution of CB-PAA 
NPs (0.6 mg/mL) at various time points; inset-close up view of 405nm peak used 
for calculations.  Bottom-Linear fitted graph of fluorescence change with 
increasing irradiation times up to five minutes.  
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Figure 2.5:  Temperature change for CB-PAA NP dissolved in DPBS at 
concentrations of 0.1, 0.6, and 1.2mg/mL.  Initial starting temperature of the 
solutions was approximately 37° C.   
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Figure 2.6:  Absorbance of CB-PAA NP dissolved in DPBS at concentrations 
between 0.1-0.35mg/mL; inset: graph of CB-PAA NP concentration versus peak 
absorbance value at 600nm used to calculate the concentration of filtered CB-
PAA NP.  
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Figure 2.7:  Fluorescent images of cells that had been previously incubated with 
CB-PAA NP and then exposed to PTT.  The images were taken before, right 
after, and every 30 minutes post treatment.  Green fluorescence indicates viable 
cells while red indicated dead cells.    
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Figure 2.8: Cell viability of HeLa cells after 24 hours incubation with increasing 
concentrations of CB-PAA nanoparticle solutions as determined by MTT assay. 
The results indicate no significant change in toxicity with increasing nanoparticle 
concentration.  Error bars represent standard error in absorbance at 550nm. 
Note: No illumination.  
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Figure 2.9:  CB-PAA NP uptake into cells after 24 hours of incubation analyzed 
by nanoparticle absorbance at 600nm.  Error bars denote standard error (n=2). 
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Figure 2.10:  Survival rates over time of the cells over a period of 3 hours after 
20 minutes of PTT with CB-PAA NP solution concentrations of 0.2-1.2mg/mL.  
Error bars denote standard error in average number of live cells per time point; 
experiments were done in triplicates, except for 0.8mg/mL, which was done in 
duplicate. Note: Shaded area is illumination time.  
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Figure 2.11:  Survival rates over time of cells treated with 0.6 mg/mL of CB-PAA 
in growth media for 24 hours with 10, 20, and 40 minutes of illumination time 
(PTT), and the control measurement (BLANK PAA NP, 40 minutes illumination 
time). Error bars represent the standard error in the average number of live cells 
at each time point; experiments were done in triplicates. All illuminations started 
at time 0.  
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